Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;108(6):532-535.
doi: 10.1111/ejh.13760. Epub 2022 Mar 7.

Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma

Ernesto Pérez-Persona  1   2 , Itziar Oiartzabal-Ormategui  3 , Susana Herraez  4 , Carmen Menchaca  2 , Laida Cuevas-Palomares  2 , Ana Santamaría-López  2 , Rosana Díez-Angulo  2 , Diego Robles-Castro  2 , Carlos de Miguel-Sánchez  2 , Miren Gabilondo-Jalón  2 , Carlos Pisón-Herrero  2 , Ariane Unamunzaga-Cilaurren  2 , Ana Vega González-Viñaspre  2 , Laura Salcedo-Cuesta  2 , Arantza Mendizabal-Abad  4 , José María Guinea de Castro  2
Affiliations

Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75-year-olds newly diagnosed with multiple myeloma

Ernesto Pérez-Persona et al. Eur J Haematol. 2022 Jun.
No abstract available

Keywords: bortezomib-melphalan-prednisone; dose intensity reduction; elderly; multiple myeloma.

PubMed Disclaimer

References

REFERENCES

    1. Remes K, Anttila P, Silvennoinen R, et al. Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland 2009-2013. PLoS One. 2018;13:2009-2013.
    1. Costa LJ, Hari PN, Kumar SK. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma. 2016;57(12):2827-2832. doi:10.3109/10428194.2016.1170828
    1. Shah JJ, Abonour R, Gasparetto C, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17:575-583.e2.
    1. Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109.
    1. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-917.

MeSH terms

LinkOut - more resources